SCHEDULE 13D/A
SCHEDULE 13D/ASchedule 13D ownership disclosure
Arcutis Biotherapeutics Inc
Common Stock, par value $0.0001 per share · CUSIP: 03969K108
Event date: 2025-08-18
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Frazier Life Sciences VIII, L.P.Reported CIK 0001655827
Shares: 8,785,284.00 · Class: 7.3%
- FHM LIFE SCIENCES VIII, L.P.Reported CIK 0001698755
Shares: 8,785,284.00 · Class: 7.4%
- FHM LIFE SCIENCES VIII, L.L.C.Reported CIK 0001698823
Shares: 8,785,291.00 · Class: 7.4%
- Frazier Life Sciences X, L.P.Reported CIK 0001790879
Shares: 27,448.00 · Class: 0.0%
- FHMLS X, L.P.Reported CIK 0001790880
Shares: 27,448.00 · Class: 0.0%
- FHMLS X, L.L.C.Reported CIK 0001790811
Shares: 27,448.00 · Class: 0.0%
- Frazier Life Sciences Public Fund, L.P.Reported CIK 0001863769
Shares: 664,973.00 · Class: 0.6%
- FHMLSP, L.P.Reported CIK 0001879466
Shares: 664,973.00 · Class: 0.6%
- FHMLSP, L.L.C.Reported CIK 0001879465
Shares: 664,973.00 · Class: 0.6%
- Frazier Life Sciences Public Overage Fund, L.P.Reported CIK 0001913804
Shares: 196,170.00 · Class: 0.2%
- FHMLSP Overage, L.P.Reported CIK 0001963247
Shares: 196,170.00 · Class: 0.2%
- FHMLSP Overage, L.L.C.Reported CIK 0001963248
Shares: 196,170.00 · Class: 0.2%
- Frazier Life Sciences XI, L.P.Reported CIK 0001911592
Shares: 73,087.00 · Class: 0.1%
- FHMLS XI, L.P.Reported CIK 0001911580
Shares: 73,087.00 · Class: 0.1%
- FHMLS XI, L.L.C.Reported CIK 0001911623
Shares: 73,087.00 · Class: 0.1%
- Frazier Life Sciences XII, L.P.Reported CIK 0002052255
Shares: 127,549.00 · Class: 0.1%
- FHMLS XII, L.P.Reported CIK 0002052246
Shares: 127,549.00 · Class: 0.1%
- FHMLS XII, L.L.C.Reported CIK 0002052177
Shares: 127,549.00 · Class: 0.1%
- James N. TopperReported CIK 0001341382
Shares: 8,843,386.00 · Class: 7.4%
- Patrick J. HeronReported CIK 0001365617
Shares: 8,943,712.00 · Class: 7.5%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001415889-25-022498
- Form type
- SCHEDULE 13D/A
- Filer
- Arcutis Biotherapeutics, Inc.
- CIK
- CIK 1787306
- Filed
- Aug 20, 2025
- Reporting period
- Aug 18, 2025
- Description
- Schedule 13D beneficial ownership